Description
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. It is a reversible inhibitor of the 26S proteasome, which is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway.
In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA.
Pharmacodynamics
Bortezomib works to target the ubiquitin-proteasome pathway, an essential molecular pathway that promotes protein degradation and maintains the homeostatic intracellular concentrations of proteins.
Mechanism of action
Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells.
Type
Small Molecule